Skip to main content

Eagle Pharmaceuticals, Inc.

EGRXDelisted Nov 26, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0000827871

Eagle Pharmaceuticals, Inc. was delisted on Nov 26, 2024; its insiders filed their last Form 4 on Mar 1, 2024; 65 institutions reported holding it in 13F filings for Q3 2024, worth $31.9M in total; no superinvestor held it.

Q3 2022 vs. Q2 2022

How the institutions holding Eagle Pharmaceuticals, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of EGRX: Q2 2022 compared with Q3 2022
MeasureQ2 2022Of which not filed for Q3 2022Q3 2022Change
Holders1641154−9
Shares11.5M5511.5M−10.8K (−0.1%)
Value$515.8M$2.00K$303.7M−$212.0M (−41.1%)

1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (22)

Institutions that held Eagle Pharmaceuticals, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Sold out (31)

Institutions that held Eagle Pharmaceuticals, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Not filed for Q3 2022 yet (1)

Institutions that held Eagle Pharmaceuticals, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding EGRX in Q2 2022 that haven't filed for Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Private Capital Group, LLC55$2.00K